Erlotinib (CAS 183321-74-6): A Comprehensive Product Introduction
Erlotinib, with the CAS number 183321-74-6, is a significant compound in the pharmaceutical and medical research fields. This article aims to provide a detailed introduction to Erlotinib, including its properties, uses, applications in various domains, and preparation methods.
Properties of Erlotinib
Erlotinib is a small – molecule tyrosine kinase inhibitor. Chemically, it has a well – defined molecular structure. Its molecular formula is \(C_{22}H_{23}N_{3}O_{4}\), and it has a molecular weight of approximately 393.44 g/mol. Physically, it appears as a white to off – white powder. It has certain solubility characteristics; it is sparingly soluble in water but more soluble in organic solvents such as dimethyl sulfoxide (DMSO). This solubility property is crucial for its formulation in different pharmaceutical products and its use in in – vitro and in – vivo research settings.
The compound has specific chemical stability under different conditions. It is relatively stable under normal storage conditions, but like many organic compounds, it may be sensitive to factors such as light, heat, and humidity. Therefore, proper storage in a cool, dry, and dark place is recommended to maintain its integrity and efficacy.
Uses of Erlotinib
Medical Therapeutics
One of the primary uses of Erlotinib is in the treatment of cancer. It is approved for the treatment of non – small cell lung cancer (NSCLC) and pancreatic cancer. In NSCLC, Erlotinib works by specifically targeting the epidermal growth factor receptor (EGFR) tyrosine kinase. EGFR is often overexpressed or mutated in NSCLC cells, leading to uncontrolled cell growth and proliferation. By inhibiting the tyrosine kinase activity of EGFR, Erlotinib blocks the downstream signaling pathways that are essential for cancer cell survival, growth, and metastasis. This results in the suppression of tumor growth and can potentially lead to tumor shrinkage and improved patient survival.
In pancreatic cancer, Erlotinib is used in combination with gemcitabine. The combination therapy has shown improved overall survival in patients with advanced pancreatic cancer. Erlotinib’s ability to target EGFR in pancreatic cancer cells helps to disrupt the cancer – promoting signaling pathways, enhancing the anti – tumor effect of gemcitabine.
Research Applications
Erlotinib is also widely used in scientific research. In cell culture studies, it is used to investigate the role of EGFR signaling in normal and cancerous cells. Researchers can use Erlotinib to block EGFR activity and observe the subsequent changes in cell behavior, such as cell proliferation, apoptosis, and migration. This helps in understanding the molecular mechanisms underlying cancer development and progression.
In animal models, Erlotinib is used to study the efficacy of EGFR – targeted therapies in pre – clinical settings. These studies can provide valuable insights into the potential side effects, optimal dosing regimens, and combination therapies that can be translated into clinical trials.
Applications in Various Domains
Oncology
In oncology, Erlotinib has revolutionized the treatment of certain types of cancers. As mentioned earlier, in NSCLC, it has become a standard treatment option, especially for patients with EGFR – activating mutations. These patients often respond better to Erlotinib compared to traditional chemotherapy, with fewer side effects. In addition to NSCLC and pancreatic cancer, ongoing research is exploring its potential use in other types of cancers, such as head and neck cancer, where EGFR overexpression is also common.
Biomedical Research
In biomedical research, Erlotinib serves as a valuable tool for studying signal transduction pathways. It helps researchers understand how EGFR – mediated signaling interacts with other cellular pathways, such as the PI3K/AKT and MAPK pathways. This knowledge can lead to the development of more effective combination therapies that target multiple pathways simultaneously, improving the overall treatment outcome for cancer patients.
Pharmaceutical Industry
In the pharmaceutical industry, Erlotinib is used as a reference compound for the development of new EGFR – targeted drugs. By comparing the efficacy and safety profiles of new compounds with Erlotinib, pharmaceutical companies can optimize the design and development of next – generation drugs. Additionally, Erlotinib is also used in the formulation development of oral dosage forms, as its solubility and stability characteristics need to be carefully considered to ensure proper drug delivery and bioavailability.
Preparation Methods of Erlotinib
Chemical Synthesis
The preparation of Erlotinib typically involves a multi – step chemical synthesis process. The starting materials are carefully selected based on their availability and reactivity. One common approach starts with the synthesis of an appropriate intermediate compound. This intermediate is then subjected to a series of chemical reactions, including substitution, condensation, and cyclization reactions.
For example, a key step in the synthesis may involve the reaction of a substituted aniline with a suitable carboxylic acid derivative to form an amide bond. This is followed by further functional group transformations, such as the introduction of a heterocyclic ring through a cyclization reaction. The final step usually involves purification processes, such as recrystallization or chromatography, to obtain pure Erlotinib.
The reaction conditions, such as temperature, pressure, and reaction time, need to be carefully controlled to ensure high yields and purity of the final product. Catalysts may also be used in some reactions to increase the reaction rate and selectivity.
Send Inquiry